GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
V

Viatris VTRS · USD

Health Care · Pharmaceuticals · US listing · 🇺🇸 United States

S&P 500

Compare

19.88

-1.97%

Close of 19 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Viatris — daily VTRS Delayed
Market value
$23.15bn
Last close × shares
Volume
9.2m
Shares, 19 Nov 2026
Dividend yield
2.50%

About Viatris

From its filings with the US Securities and Exchange Commission

SEC filings

Viatris is based in Canonsburg, Pennsylvania and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker VTRS. It is a member of the S&P 500. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $14.30bn and a net loss of $3.51bn. At that date it held total assets of $37.19bn and shareholders' equity of $14.71bn.

In its own words

Viatris is a global healthcare company whose breadth and scale we believe make it uniquely positioned to address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, Viatris supplies high-quality medicines to approximately 1 billion patients around the world each year. The Company has a global footprint, an extensive portfolio of medicines that is well-diversified across therapeutic areas, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges.

Viatris’ executive management team is focused on ensuring that the Company is optimally structured and efficiently resourced to deliver sustainable value to patients, shareholders, customers and other key stakeholders. The Company operates in more than 165 countries and territories with more than 30,000 employees. The Company has 27 manufacturing, packaging, and distribution sites worldwide, more than 1,400 approved molecules, and what we believe is industry leading commercial, R&D, regulatory, manufacturing, legal and medical expertise. Viatris’ portfolio consists of generics (including complex products), globally recognized iconic brands, and an expanding portfolio of innovative medicines. Viatris is headquartered in the U.S., with global centers in Pittsburgh, Pennsylvania, Shanghai, China and Hyderabad, India.

Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗

More about Viatris →

How it makes its money

Revenue, year to 31 Dec 2025

  • Brands $9.18bn · 64.4%
  • Generics $5.07bn · 35.6%
  • Lipitor ® $1.55bn · 10.9%
  • Norvasc ® $709.9m · 5.0%

Latest on Viatris

Our reporting

Next results

25 Feb 2027

Due on 25 Feb 2027. Analysts expect earnings of 0.60 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Viatris's ticker?

Viatris trades as VTRS on its US listing, under ISIN US92556V1061.

What was Viatris's last closing price?

19.88 on 19 Nov 2026. The figure is in USD and is never converted.

When does Viatris next report results?

Results are expected on 5 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.